Colgate Palmolive (CL) Common Equity (2009 - 2026)

Colgate Palmolive's Common Equity history runs 18 years deep, the most recent figure standing at $486.0 million for Q1 2026.

• In Q1 2026, Common Equity rose 101.76% year-over-year to $486.0 million; the TTM figure through Mar 2026 stood at $486.0 million (up 101.76% YoY), while the FY2025 annual figure was $365.0 million, up 9.94% from the prior year.
• Common Equity was $486.0 million for Q1 2026 at Colgate Palmolive, up from $365.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $25.5 billion in Q2 2024 to a low of -$27.6 billion in Q1 2025.
• Historically, Common Equity has averaged -$3.5 billion across 5 years, with a median of $348.0 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Common Equity sank 405400.0% in 2022, then surged 199.78% in 2024.
• A 5-year view of Common Equity shows it stood at -$4.1 billion in 2022, then soared by 108.58% to $348.0 million in 2023, then retreated by 4.6% to $332.0 million in 2024, then gained by 9.94% to $365.0 million in 2025, then jumped by 33.15% to $486.0 million in 2026.
• The last three Common Equity figures came in at $486.0 million (Q1 2026), $365.0 million (Q4 2025), and $856.0 million (Q3 2025), per Business Quant data.